CCR8 depletion reverses resistance to radiotherapy and PD-1 blockade in preclinical head and neck cancer

Depleting CCR8-positive regulatory T cells improved locoregional control and reversed resistance to radiotherapy plus anti-PD-1 in mouse head and neck cancer models.

KEY POINTS

  • This translational study investigated CCR8-positive regulatory T cells (Tregs) as mediators of resistance to radiation and PD-1 blockade in head and neck squamous cell carcinoma (HNSCC). Investigators combined human tumor transcriptomic datasets, paired tumor and normal tissue from a previous phase I/Ib trial (NCT03635164), and multiple orthotopic murine models, including Ly2, mEER, P029, MOC1, and MOC2. CCR8 expression was enriched in immunosuppressive tumor-infiltrating Tregs and was significantly higher in human tumor tissue than matched adjacent normal tissue (p=0.03).
  • Radiation altered intratumoral CCR8-positive immune populations in a dose- and model-dependent manner. In the mEER model, single-fraction irradiation with 2, 4, 10, or 20 Gy increased CCR8-expressing CD4-positive cells over time, particularly after higher doses. However, these cells were predominantly FOXP3-negative activated T cells at day seven, whereas in the Ly2 model, 10 Gy increased CCR8-positive cells largely within the FOXP3-positive Treg compartment. This distinction demonstrates that CCR8 expression is not restricted exclusively to suppressive T cells in every tumor context.
  • Adding CCR8-depleting antibodies to RT markedly improved local tumor control. In the Ly2 model, 10 Gy plus 2 μg anti-CCR8 achieved initial local control in 9/10 mice, while 10 Gy plus 200 μg anti-CCR8 achieved initial control in 10/10 mice. Neither RT alone nor antibody monotherapy produced comparable tumor eradication. The higher antibody dose significantly reduced subsequent locoregional recurrence compared with the lower dose (p=0.0026), with improved survival and resistance to tumor rechallenge among successfully treated animals.
  • The benefit extended to hypofractionated RT in additional models. With 8 Gy × 3 fractions, adding anti-CCR8 reduced local recurrence from 3/10 to 0/10 mice in the mEER model (p=0.06) and from 5/10 to 0/10 in the P029 model (p=0.011). These findings support an effect on recurrence after initial tumor eradication, although the mEER comparison did not reach conventional statistical significance. In a separate A074 model prone to distant lung metastases, the combination improved primary tumor response but did not reduce lung metastatic disease.
  • PD-1 blockade unexpectedly worsened radiation response in selected resistant models. In anti-PD-1-resistant mEER tumors, adding anti-PD-1 to RT accelerated tumor growth compared with RT alone. This antagonistic effect was reversed when CCR8-positive cells were depleted, with RT plus anti-CCR8, with or without anti-PD-1, significantly improving tumor growth control and survival relative to RT plus anti-PD-1 (p<0.001). Adding anti-PD-1 to RT plus anti-CCR8 did not consistently produce a significant additional survival benefit, emphasizing the importance of tumor-specific resistance mechanisms.
  • CCR8 depletion remodeled the tumor immune microenvironment. Treatment reduced CCR8-positive Tregs, increased intratumoral CD8-positive and conventional CD4-positive T-cell populations, and increased markers of cytotoxic activation, including granzyme B and Ki67. Combined RT and anti-CCR8 reduced immunosuppressive myeloid-derived suppressor cells and PD-1/LAG3 co-expression in CD8-positive cells. Complementary Treg experiments indicated that anti-PD-1 exposure could increase immunosuppressive markers, including FOXP3, CD25, CTLA-4, and TGFβ, providing a plausible mechanism for resistance.
  • These results are preclinical and cannot establish benefit in patients receiving contemporary immunotherapy. Although human HNSCC data support CCR8 enrichment within tumor-associated immune populations, anti-CCR8 treatment efficacy was evaluated only in experimental systems. CCR8 expression varied across immune subsets and tumor models, and the combination did not consistently prevent distant metastasis. Clinical studies must establish suitable biomarkers, antibody dosing, immune toxicity, and whether CCR8 depletion improves outcomes when added to standard radiotherapy and checkpoint blockade.

CLINICAL TAKEAWAY

CCR8-positive regulatory T cells appear to contribute to resistance to radiotherapy and PD-1 blockade in selected head and neck cancer models, and their depletion can substantially improve locoregional tumor control. The unexpected observation that PD-1 blockade may amplify Treg-mediated suppression in resistant tumors provides a mechanistic rationale for more selective immune modulation. These findings remain preclinical and require prospective human validation before CCR8-targeted treatment can be considered a clinical radioimmunotherapy strategy.

SOURCE

Nature Communications

Browse more research Suggest a correction